Researchers are looking to solve PTSD. Could MDMA-assisted therapies provide an answer?
Due perhaps to prejudice and precedent, the FDA and pharmaceutical industry have long shied away from testing controlled substances as therapies for a range of hard-to-treat mental disorders. But the ice is thawing, and a landmark Phase III test for psychedelic MDMA has turned out some promising results.
Eighty-eight percent of PTSD patients who received three MDMA-assisted talk therapy sessions reported clinically meaningful reductions in symptoms compared with patients who received placebo (p=<0.0001), according to data from a Phase III study sponsored by the Multidisciplinary Association of Psychedelic Studies (MAPS) unveiled Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.